Abstract
New macrolides, such as clarithromycin and azithromycin, are active agents to Mycobacterium avium complex (MAC). Both clarithromycin and azithromycin are well-known for the ability to improve the prognosis of AIDS patients with disseminated MAC infection. However, the administration of monotherapy with a macrolide is usually associated with the emergence of drug resistance after a few months of use. Therefore, the recommended treatment for MAC infection involved the use of at least two antibiotics, which includes a macrolide in combination with rifabutin, moxifloxacin and / or ethambutol. When used as prophylactic therapy in AIDS patients, azithromycin is more convenient (1200 mg, once a week) than clarithromycin (500 mg, twice a day). Ketolides are a semi-synthetic derivative of erythromycin A, which differs from erythromycin A by substitution of a 3- keto group for L-cladinose. Telithromycin has a carbamate group linked to an imidazolium and pyridium nucleus at C11- C12. In mice model, both telithromycin and ABT-733 were active in vivo against MAC.
Keywords: macrolides, clarithromycin, azithromycin, roxithromycin
Current Pharmaceutical Design
Title: Effects of Macrolides and Ketolides on Mycobacterial Infections
Volume: 10 Issue: 26
Author(s): Luiz E. Bermudez and Yoshitaka Yamazaki
Affiliation:
Keywords: macrolides, clarithromycin, azithromycin, roxithromycin
Abstract: New macrolides, such as clarithromycin and azithromycin, are active agents to Mycobacterium avium complex (MAC). Both clarithromycin and azithromycin are well-known for the ability to improve the prognosis of AIDS patients with disseminated MAC infection. However, the administration of monotherapy with a macrolide is usually associated with the emergence of drug resistance after a few months of use. Therefore, the recommended treatment for MAC infection involved the use of at least two antibiotics, which includes a macrolide in combination with rifabutin, moxifloxacin and / or ethambutol. When used as prophylactic therapy in AIDS patients, azithromycin is more convenient (1200 mg, once a week) than clarithromycin (500 mg, twice a day). Ketolides are a semi-synthetic derivative of erythromycin A, which differs from erythromycin A by substitution of a 3- keto group for L-cladinose. Telithromycin has a carbamate group linked to an imidazolium and pyridium nucleus at C11- C12. In mice model, both telithromycin and ABT-733 were active in vivo against MAC.
Export Options
About this article
Cite this article as:
Bermudez E. Luiz and Yamazaki Yoshitaka, Effects of Macrolides and Ketolides on Mycobacterial Infections, Current Pharmaceutical Design 2004; 10 (26) . https://dx.doi.org/10.2174/1381612043383241
DOI https://dx.doi.org/10.2174/1381612043383241 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Comprehensive View on Metabolic Pathway Analysis Methodologies
Current Bioinformatics Recent Advances in Tuberculosis Vaccine Development
Current Respiratory Medicine Reviews Monoterpenoid Geraniol Improves Anti-mycobacterial Drug Efficiency by Interfering with Lipidome and Virulence of Mycobacteria
Infectious Disorders - Drug Targets QSAR Studies, Synthesis and Antibacterial Assessment of New Inhibitors Against Multidrug-Resistant Mycobacterium tuberculosis
Current Drug Discovery Technologies Proteomic Study of the Mechanism of Talin-C as an Inhibitor of HIV Infection
Current Proteomics An Overview of the Antimicrobial Activity of Polymeric Nanoparticles Against Enterobacteriaceae
Current Pharmaceutical Design Biologic Therapies in Primary Sjögren's Syndrome
Current Pharmaceutical Biotechnology Spoligotyping for Identification of Pulmonary Tuberculosis with Type 2 Diabetes Mellitus Profiles in Warangal, T.S.
Anti-Infective Agents FDG-PET Imaging in Sarcoidosis
Current Medical Imaging Developing Country Applications of Molecular Farming: Case Studies in South Africa and Argentina
Current Pharmaceutical Design Mycotherapy of Cancer: An Update on Cytotoxic and Antitumor Activities of Mushrooms, Bioactive Principles and Molecular Mechanisms of their Action
Current Topics in Medicinal Chemistry Heat Shock Proteins: Therapeutic Perspectives in Inflammatory Disorders
Recent Patents on Inflammation & Allergy Drug Discovery <i>In Silico</i> Prediction of Epitopes in Virulence Proteins of Mycobacterium ulcerans for Vaccine Designing
Current Genomics Recent Advances in Adenylation Domain Enzymology in Nonribosomal Peptide Biosynthesis
Current Organic Chemistry Editorial (Thematic Issue: Medicinal Chemistry Applied to Natural Products in Neglected Drug Discovery)
Combinatorial Chemistry & High Throughput Screening Therapeutic Use of Chemokines
Current Pharmaceutical Design C-Type Lectins on Dendritic Cells and Their Interaction with Pathogen-Derived and Endogenous Glycoconjugates
Current Protein & Peptide Science Synthesis, Antibacterial and Antioxidant Activities of Some New Nsubstituted Azachalcone, Schiff base and Pyrazole Derivatives
Letters in Organic Chemistry A Therapeutic Connection between Dietary Phytochemicals and ATP Synthase
Current Medicinal Chemistry New Insights into Ocular Complications of Human Immunodeficiency Virus Infection
Current HIV Research